JAHA:生病也要挑“吉时”——学术会议期间急性心梗患者的死亡率更低!

2018-03-10 MedSci MedSci原创

既往有研究报道在国际心血管学术会议期间,教学医院的急性心血管事件的30天死亡率更低。本研究纳入分析了2007年至2013年有国际心血管学术会议期间的主要教学医院的急性心梗住院患者的30天死亡率,并对比分析了非会议期间的死亡率。分析结果发现,非调整和调整后的患者30天死亡率在国际心血管学术会议期间住院的患者中更低(非调整:15.3% [482/3153] vs 16.7% [5208/31 556]

既往有研究报道在国际心血管学术会议期间,教学医院的急性心血管事件的30天死亡率更低。

本研究纳入分析了2007年至2013年有国际心血管学术会议期间的主要教学医院的急性心梗住院患者的30天死亡率,并对比分析了非会议期间的死亡率。分析结果发现,非调整和调整后的患者30天死亡率在国际心血管学术会议期间住院的患者中更低(非调整:15.3% [482/3153] vs 16.7% [5208/31 556] [P=0.04];调整后:15.4% vs 16.7%; [P=0.05])。心脏介入的干预率在两组患者之前是相似的(59.5% vs 59.8%; P=0.88),经皮冠脉介入比率也相似(30.2% vs 29.1%; P=0.20)。死亡率降低最多的患者是未接受经皮冠脉介入治疗的非ST段抬高型梗死患者(16.9% vs 19.5%; P=0.008)。

研究结果显示,急性心梗患者的30天死亡率在国际心血管学术会议期间要更低,尤其是非ST段抬高型梗死患者。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049475, encodeId=f00020494e529, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 07 06:34:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904705, encodeId=0a8f1904e052f, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Sep 10 22:34:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267761, encodeId=ab44126e76103, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308368, encodeId=33801308368c1, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294838, encodeId=e39c2948387c, content=不错哟.有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:41:27 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049475, encodeId=f00020494e529, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 07 06:34:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904705, encodeId=0a8f1904e052f, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Sep 10 22:34:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267761, encodeId=ab44126e76103, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308368, encodeId=33801308368c1, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294838, encodeId=e39c2948387c, content=不错哟.有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:41:27 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049475, encodeId=f00020494e529, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 07 06:34:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904705, encodeId=0a8f1904e052f, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Sep 10 22:34:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267761, encodeId=ab44126e76103, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308368, encodeId=33801308368c1, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294838, encodeId=e39c2948387c, content=不错哟.有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:41:27 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
    2018-03-12 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049475, encodeId=f00020494e529, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 07 06:34:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904705, encodeId=0a8f1904e052f, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Sep 10 22:34:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267761, encodeId=ab44126e76103, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308368, encodeId=33801308368c1, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294838, encodeId=e39c2948387c, content=不错哟.有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:41:27 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2049475, encodeId=f00020494e529, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 07 06:34:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904705, encodeId=0a8f1904e052f, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Sep 10 22:34:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267761, encodeId=ab44126e76103, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308368, encodeId=33801308368c1, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Mar 12 01:34:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294838, encodeId=e39c2948387c, content=不错哟.有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:41:27 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
    2018-03-10 owlhealth

    不错哟.有意思

    0

相关资讯

Lancet Diabetes Endo:GLP-1受体激动剂是否有心血管保护作用?

糖尿病和心血管病是难兄难弟,二者常常如影相随。有数据表明,约七成糖尿病人最终死于心血管意外。因此,降糖药物具有降低心血管风险的获益尤为重要。

JACC:大误!体重减少并不会降低冠心病死亡风险!

冠心病患者被推荐应积极体育锻炼,以维持一个健康的体重。本研究的目的旨在评估冠心病患者体重指数(BMI)和体育锻炼强度(PA)的变化与死亡率间的关系。本研究纳入了3307名(女性占1038名)冠心病患者,在30年的随访时间里,有1493名患者死亡(55%为心血管源性死亡),体重的减少(BMI<-0.10 kg/m2/年)与全因死亡率的升高相关(HR: 1.30; 95% [CI]: 1.12

JACC:心血管医师需终身学习 在职教育体系怎样改进?

人们都说“活到老,学到老”,学习不仅是每个人终其一生应该坚持的习惯,对医生这一特殊群体而言,更是不断提升医术、精进业务的一大法宝。心血管疾病是全球的头号死因,在2012年死于该疾病的人数占总数的31%。考虑到心血管医师的职业培养是卫生建设的重中之重,2018年1月,发表在《J Am Coll Cardiol》的一项美国研究,探索了心血管医师终身学习的教育新体系。

JACC:NOACs并不会增加房颤患者肝脏损伤的风险

非维生素K拮抗剂口服抗凝剂(NOACs)常被用来预防非瓣膜性房颤(NVAF)患者卒中的发生,然而其可能对肝脏的毒性会限制他的应用。本研究的目的旨在评估比较NOACs和维生素K拮抗剂(VKAs)对NVAF患者肝脏损伤的影响。本研究共纳入了51887名2011年至2014年新诊断的NVAF患者,其中3778名患者有肝脏疾病史。经过68739人年时间的随访,有585名患者出现有严重的肝脏损害,与VKAs

JACC:心血管疾病医疗费用给社会带来巨大负担

心血管疾病(CVD)对美国乃至全世界都造成了巨大的经济负担。本研究的目的旨在评估MESA临床研究中6814名无症状的参与者10年来的医疗保健费用。本研究对参与者10年来的累积的心血管疾病药物治疗、随访、诊断、冠状动脉血运重建和住院治疗的费用进行了详细的评估。分析结果发现,10年来的危险因素发病率明显增高,糖尿病、高血压和高血脂增高的比例分别是19%、57%和53%。患者自我报道的症状(比如胸痛或气

JACC:血清地高辛水平与房颤患者死亡风险相关!

地高辛在房颤患者中的应用非常广泛。本研究的目的旨在评估地高辛的使用是否与房颤患者死亡率的增高相关。本研究纳入了17897名房颤患者,并在新使用地高辛治疗患者和匹配对照之间比较分析地高辛的使用与患者死亡率之间的关系。在研究的基线水平,共有5824名(32.5%)患者接受有地高辛的治疗,结果分析发现基线水平地高辛的使用与患者的死亡风险无明显相关性([HR]: 1.09; 95% [CI]: 0.96-